Clinical Trials Browser

selinexor × Gynecologic × 1 year × Clear all

Genital Diseases, Neoplasms, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Endometrial Neoplasms

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05611931 2026-02-02

XPORT-EC-042

Phase 3 Recruiting

276 enrolled

Gynecologic

Endometrial Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04811196 2025-05-29

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients

Phase 1 Completed

56 enrolled

GynecologicSarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Endometrial Stromal, Neurofibrosarcoma

Clinical Trials

ENGOT-EN5

KEAP

XPORT-EC-042

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients